Fundraise

CoFlo Medical raises $6M Seed to rethink the injection needle

What's the deal? CoFlo MedicalDealroom has a profile for this one. Try Dealroom →, a San Francisco drug-delivery company, has raised a $6 million Seed round led by J2 VenturesDealroom has a profile for this one. Try Dealroom →, chief executive officer and cofounder Simon Rufer announced on November 19, 2026. The MIT spinout is building equipment that could give pharmaceutical developers more freedom in the formulations they choose.

What's the endgame? CoFlo's core annular flow technology surrounds a viscous medicine with a lower-viscosity fluid as both pass through the needle. That addresses a practical constraint on concentrated injectables: a smaller dose can arrive in a liquid that is harder to push. The company's technical FAQ notes the surrounding sheath must be compatible with the drug and travels along with it.

The science: The approach has published research behind it. A 2020 paper in Advanced Healthcare Materials , coauthored by cofounders Vishnu Jayaprakash and MIT professor Kripa Varanasi, reported up to a sevenfold reduction in injection force using coaxial lubrication. A September 2026 company article reported a 100-fold force reduction in specified demonstrations — results tied to particular formulations and conditions, not universal claims.

Why now? CoFlo won MIT's $100K entrepreneurship competition in May 2025, recognising the venture before the latest financing. Rufer is CEO, Jayaprakash is chief business officer, and Varanasi is chairman.

What could go wrong? The useful configuration — CoFlo lists Gen One, Double Barrel, and CO-AXL hub options — depends on the medicine, container, and administration setting. That makes for a commercial relationship more involved than selling a syringe attachment. The prize and funding do not resolve the separate questions of product commercialisation or clinical adoption.

A note on the numbers: A 2025 SEC Form D recorded a $6 million offering with $500,000 sold at that point. Rufer's announcement supplies the current Seed figure; the disclosures do not specify a valuation, the full syndicate, or how proceeds will be allocated.

The signal: A modest Seed round — roughly in line with peers like TesoraiDealroom has a profile for this one. Try Dealroom →'s $5.3 million and TouchmarkDealroom has a profile for this one. Try Dealroom →'s $3 million — is betting that the delivery hardware, not just the molecule, can expand which treatments reach patients.

Read more: devcuration.com

Image credit: Generated with Gemini

More top stories